Castle Creek

9 items

May 19, 2020

Philadelphia Magazine features a Paragon portfolio company as a leader in cell and gene therapy innovation
May 19, 2020 – We are proud to share [...]
December 16, 2019

Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science
– Acquisition complements and expands Castle Creek [...]
October 19, 2018

Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma
Paragon organizes new investment from Fidelity Management [...]
October 1, 2018

Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018
Paragon CEO Jeff Aronin Recognized by Insights Care [...]
August 9, 2018

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex
Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) [...]
June 25, 2018

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
New multi-center Phase 1 study expected to [...]
May 16, 2018

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
PARSIPPANY, N.J., May 16, 2018 – Castle Creek [...]
January 4, 2018

Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit
Biopharma company developing therapies for orphan dermatologic conditions [...]